Statins and risk of breast cancer recurrence

Minas Sakellakis,1 Karolina Akinosoglou,1 Anastasia Kostaki,2 Despina Spyropoulou,1 Angelos Koutras,1 1Department of Medicine, Division of Oncology, University Hospital, Patras Medical School, Patras, 2Department of Statistics, Athens University of Economics and Business, Athens, Greece Background:...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sakellakis M, Akinosoglou K, Kostaki A, Spyropoulou D, Koutras A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Statins breast cancer adjuvant recurrence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1fee0ecef66f4dcab8ca73d84845c9ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1fee0ecef66f4dcab8ca73d84845c9ae
record_format	dspace
spelling	oai:doaj.org-article:1fee0ecef66f4dcab8ca73d84845c9ae2021-12-02T02:51:13ZStatins and risk of breast cancer recurrence1179-1314https://doaj.org/article/1fee0ecef66f4dcab8ca73d84845c9ae2016-11-01T00:00:00Zhttps://www.dovepress.com/statins-and-risk-of-breast-cancer-recurrence-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Minas Sakellakis,1 Karolina Akinosoglou,1 Anastasia Kostaki,2 Despina Spyropoulou,1 Angelos Koutras,1 1Department of Medicine, Division of Oncology, University Hospital, Patras Medical School, Patras, 2Department of Statistics, Athens University of Economics and Business, Athens, Greece Background: The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. Materials and methods: We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence. Results: Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapse-free survival (16.6 vs 10.2 years, P=0.028). After data had been adjusted for patient and disease characteristics, statin users maintained a lower risk of recurrence. This favorable outcome in statin users was particularly evident when we included only younger patients in the analysis (20 vs 10 years, P=0.006). Conclusion: Statins may be linked to a favorable outcome in early breast cancer patients, especially in younger age-groups. Keywords: statins, breast, cancer, adjuvant, recurrenceSakellakis MAkinosoglou KKostaki ASpyropoulou DKoutras ADove Medical PressarticleStatinsbreastcanceradjuvantrecurrenceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 8, Pp 199-205 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Statins breast cancer adjuvant recurrence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Statins breast cancer adjuvant recurrence Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sakellakis M Akinosoglou K Kostaki A Spyropoulou D Koutras A Statins and risk of breast cancer recurrence
description	Minas Sakellakis,1 Karolina Akinosoglou,1 Anastasia Kostaki,2 Despina Spyropoulou,1 Angelos Koutras,1 1Department of Medicine, Division of Oncology, University Hospital, Patras Medical School, Patras, 2Department of Statistics, Athens University of Economics and Business, Athens, Greece Background: The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. Materials and methods: We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence. Results: Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapse-free survival (16.6 vs 10.2 years, P=0.028). After data had been adjusted for patient and disease characteristics, statin users maintained a lower risk of recurrence. This favorable outcome in statin users was particularly evident when we included only younger patients in the analysis (20 vs 10 years, P=0.006). Conclusion: Statins may be linked to a favorable outcome in early breast cancer patients, especially in younger age-groups. Keywords: statins, breast, cancer, adjuvant, recurrence
format	article
author	Sakellakis M Akinosoglou K Kostaki A Spyropoulou D Koutras A
author_facet	Sakellakis M Akinosoglou K Kostaki A Spyropoulou D Koutras A
author_sort	Sakellakis M
title	Statins and risk of breast cancer recurrence
title_short	Statins and risk of breast cancer recurrence
title_full	Statins and risk of breast cancer recurrence
title_fullStr	Statins and risk of breast cancer recurrence
title_full_unstemmed	Statins and risk of breast cancer recurrence
title_sort	statins and risk of breast cancer recurrence
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/1fee0ecef66f4dcab8ca73d84845c9ae
work_keys_str_mv	AT sakellakism statinsandriskofbreastcancerrecurrence AT akinosoglouk statinsandriskofbreastcancerrecurrence AT kostakia statinsandriskofbreastcancerrecurrence AT spyropouloud statinsandriskofbreastcancerrecurrence AT koutrasa statinsandriskofbreastcancerrecurrence
_version_	1718402089651011584

Statins and risk of breast cancer recurrence

Ejemplares similares